GHK-Cu: Preclinical Research Overview

What is GHK-Cu?

GHK-Cu (copper-tripeptide-1) is a naturally-occurring tripeptide — glycyl-L-histidyl-L-lysine — complexed with a single copper(II) ion. The peptide was originally isolated from human plasma in the 1970s by Pickart and Thaler, where it was observed to influence the expression of liver tissue from older donors in cell-culture studies.[1]

Plasma concentrations of GHK decline measurably with age — one of the reasons it has drawn sustained research interest as a tool compound in tissue-repair, dermal-fibroblast and antioxidant-pathway models. The synthetic form supplied for research use is chemically identical to the endogenous peptide, with the copper centre intact.

Mechanisms Studied in Preclinical Research

Across the in vitro and animal-model literature, GHK-Cu has been associated with several signalling and biosynthetic pathways. The following describe research observations only — not therapeutic effects.

Collagen & elastin gene expression

Cultured dermal fibroblast studies have reported associations between GHK-Cu exposure and the expression of genes encoding type I collagen, elastin, decorin and glycosaminoglycans — the structural matrix components that give connective tissue its tensile strength and elasticity.[2]

Antioxidant & copper-transport activity

GHK-Cu is studied as a research tool in the context of copper trafficking in tissue, and in association with antioxidant enzyme activity (including superoxide dismutase) in cell-culture oxidative-stress models.[3]

Wound-response & angiogenesis models

Rodent and in vitro models examining GHK-Cu in tissue-response contexts have reported observations on angiogenic signalling, fibroblast migration and matrix remodelling — commonly used readouts in repair-pathway research.[4]

Key Research Literature

GHK-Cu has been studied since the 1970s, with the bulk of the modern preclinical literature originating from the research group of Loren Pickart and collaborators, with additional work from Maquart and others. Selected representative work:

Summaries above are derived from publicly available peer-reviewed literature and describe research observations only. They are not claims of efficacy or safety in humans.

Handling in the Laboratory

Velox GHK-Cu is supplied as lyophilised (freeze-dried) powder with the copper centre intact (typically presented as a deep-blue powder, characteristic of the GHK-Cu(II) complex). For research use it is reconstituted with bacteriostatic water; our reconstitution calculator assists with concentration calculations.

• Lyophilised storage: −20°C, dry and dark.
• Reconstituted storage: 2–8°C; avoid freeze–thaw cycles; protect from light.
• Verification: every batch is third-party HPLC-tested; batch documentation available on request.

References

1. Pickart L — foundational identification and characterisation of GHK and its copper complex; multiple journals. PubMed.
2. Maquart F-X, et al. — GHK-Cu and matrix glycosaminoglycan / collagen expression in dermal fibroblast research. PubMed.
3. Pickart L, Margolina A — reviews of GHK and gene-expression / antioxidant pathway research. PubMed.
4. Research examining GHK-Cu in angiogenesis, fibroblast migration and matrix remodelling models. PubMed.

Frequently Asked Questions